SG47501A1 - N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present - Google Patents

N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present

Info

Publication number
SG47501A1
SG47501A1 SG1996002367A SG1996002367A SG47501A1 SG 47501 A1 SG47501 A1 SG 47501A1 SG 1996002367 A SG1996002367 A SG 1996002367A SG 1996002367 A SG1996002367 A SG 1996002367A SG 47501 A1 SG47501 A1 SG 47501A1
Authority
SG
Singapore
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Application number
SG1996002367A
Other languages
English (en)
Inventor
Dino Nisato
Claude Plouzane
Claudine Serradeil-Legal
Bernard Tonnerre
Jean Wagon
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG47501A1 publication Critical patent/SG47501A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
SG1996002367A 1991-08-02 1992-08-03 N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present SG47501A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (fr) 1991-08-02 1991-08-02 Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.

Publications (1)

Publication Number Publication Date
SG47501A1 true SG47501A1 (en) 1998-04-17

Family

ID=9415909

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996002367A SG47501A1 (en) 1991-08-02 1992-08-03 N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present

Country Status (29)

Country Link
EP (1) EP0526348B1 (hu)
JP (1) JP2633085B2 (hu)
KR (1) KR100241583B1 (hu)
AT (1) ATE163289T1 (hu)
AU (2) AU658664B2 (hu)
BR (1) BR9205336A (hu)
CA (2) CA2093221C (hu)
CZ (1) CZ288173B6 (hu)
DE (1) DE69224450T2 (hu)
DK (1) DK0526348T3 (hu)
ES (1) ES2117038T3 (hu)
FI (2) FI104069B1 (hu)
FR (1) FR2679903B1 (hu)
HK (1) HK1008741A1 (hu)
HU (2) HUT68927A (hu)
IL (3) IL117592A (hu)
LT (1) LT3064B (hu)
LV (1) LV10091B (hu)
MX (1) MX9204487A (hu)
MY (1) MY110517A (hu)
NO (1) NO180047C (hu)
NZ (1) NZ243795A (hu)
PH (1) PH30661A (hu)
RU (1) RU2104268C1 (hu)
SG (1) SG47501A1 (hu)
SK (1) SK283463B6 (hu)
UA (1) UA27238C2 (hu)
WO (1) WO1993003013A1 (hu)
ZA (1) ZA925781B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
FR2708608B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
CA2290748A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006433A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9812111A (pt) * 1997-07-31 2000-07-18 Elan Pharm Inc Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2775598A1 (fr) 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
FR2786486B3 (fr) * 1998-11-16 2000-12-08 Sanofi Sa Procede de preparation du (2s)-1-[(2r,3s)-5-chloro-3-(2- chlorophenyl)-1-(3,4-dimethoxy benzenesulfonyl)-3-hydroxy- 2,3-dihydro-1h-indole-2-carbonyl]pyrrolidine-2-carboxamide, de ses solvats et/ou hydrates
AR035476A1 (es) 1999-01-22 2004-06-02 Elan Pharm Inc Compuestos heteroarilo y heterociclicos con anillo fusionado, los cuales inhiben la adhesion de leucocitos mediada por vla-4, composiciones farmaceuticas, el uso de las mismas para la manufactura de un medicamento y un metodo para fijar vla-4 en una muestra biologica
BR0007663A (pt) 1999-01-22 2002-05-07 Elan Pharm Inc Derivados de acila para uso no tratamento de doenças relacionadas com o vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
MXPA01007394A (es) * 1999-01-25 2002-04-09 Wyeth Corp Compuestos que inhiben la adhesion de leucocitos mediada mediante alfa4 beta1 integrina y cd49d/cd29 (vla-4).
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2792834A1 (fr) * 1999-04-29 2000-11-03 Sanofi Sa Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805992A1 (fr) * 2000-03-08 2001-09-14 Sanofi Synthelabo Compositions pharmaceutiques orales contenant des derives de n-sulfonylindoline
CA2423933A1 (en) 2000-10-17 2002-04-25 Applied Research Systems Ars Holding N.V. Pharmaceutically active sulfanilide derivatives
EP1338597A4 (en) 2000-11-28 2008-06-18 Astellas Pharma Inc DERIVATIVES OF 1,4,5,6-TETRAHYDROIMIDAZO 4,5-D DIAZEPINE OR SALTS THEREOF
JP4044740B2 (ja) * 2001-05-31 2008-02-06 信越化学工業株式会社 レジスト材料及びパターン形成方法
EP1458381B1 (en) 2001-12-20 2005-11-30 Applied Research Systems ARS Holding N.V. Triazoles as oxytocin antagonists
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
MXPA04011465A (es) 2002-05-24 2005-02-14 Millennium Pharm Inc Inhibidores de ccr9 y metodos de uso de los mismos.
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
EP1554239B1 (en) * 2002-10-11 2011-01-26 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
PT1798223E (pt) 2002-11-18 2011-10-17 Chemocentryx Inc Aril-sulfonamidas
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
BRPI0616687A2 (pt) 2005-09-29 2011-06-28 Elan Pharm Inc compostos de pirimidinil amida que inibem a adesão leucocitária mediada por vla-4
CA2624524C (en) 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
TWI389904B (zh) 2006-02-27 2013-03-21 Elan Pharm Inc 抑制由ｖｌａ-４所調節的白血球黏附之嘧啶磺醯胺化合物
SG175355A1 (en) 2009-04-27 2011-12-29 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
MY110517A (en) 1998-07-31
FR2679903A1 (fr) 1993-02-05
SK42693A3 (en) 1993-10-06
ATE163289T1 (de) 1998-03-15
CA2206776A1 (en) 1993-02-03
DE69224450D1 (de) 1998-03-26
JPH06501960A (ja) 1994-03-03
CA2206776C (en) 2002-02-26
HUT68927A (en) 1995-08-28
JP2633085B2 (ja) 1997-07-23
NO180047C (no) 1997-02-05
LTIP114A (en) 1994-06-15
PH30661A (en) 1997-09-16
CA2093221A1 (en) 1993-02-03
EP0526348B1 (fr) 1998-02-18
DE69224450T2 (de) 1998-07-30
IL117592A0 (en) 1996-07-23
NZ243795A (en) 1995-04-27
WO1993003013A1 (fr) 1993-02-18
AU2475892A (en) 1993-03-02
AU1154195A (en) 1995-05-04
NO931262D0 (no) 1993-04-01
EP0526348A1 (fr) 1993-02-03
FI980175A (fi) 1998-01-27
FR2679903B1 (fr) 1993-12-03
AU691223B2 (en) 1998-05-14
RU2104268C1 (ru) 1998-02-10
KR100241583B1 (ko) 2000-03-02
ZA925781B (en) 1993-03-02
NO931262L (no) 1993-05-26
UA27238C2 (uk) 2000-08-15
CZ68293A3 (en) 1994-01-19
DK0526348T3 (da) 1998-11-23
LT3064B (en) 1994-10-25
FI104069B (fi) 1999-11-15
FI931476A (fi) 1993-04-01
MX9204487A (es) 1993-02-01
AU658664B2 (en) 1995-04-27
CA2093221C (en) 1998-09-22
HU9300951D0 (en) 1993-06-28
FI980175A0 (fi) 1998-01-27
IL102703A0 (en) 1993-01-14
HU211884A9 (en) 1995-12-28
HK1008741A1 (en) 1999-05-14
SK283463B6 (sk) 2003-08-05
CZ288173B6 (en) 2001-05-16
IL102703A (en) 1997-03-18
BR9205336A (pt) 1993-11-16
FI104069B1 (fi) 1999-11-15
IL117592A (en) 1999-04-11
FI931476A0 (fi) 1993-04-01
LV10091A (lv) 1994-05-10
LV10091B (en) 1995-04-20
FI107048B (fi) 2001-05-31
ES2117038T3 (es) 1998-08-01
NO180047B (no) 1996-10-28

Similar Documents

Publication Publication Date Title
SG47501A1 (en) N-sulfonyl indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present
PT81748A (en) Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof
SG49053A1 (en) Arylalkylamines process for preparing them and pharmaceutical compositions containing them
NZ333926A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
DE3783657D1 (de) Peptide mit einfluss auf die diurese und natriurese, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
ATE189459T1 (de) Peptide mit endothelin antagonistischer aktivitaet. deren herstellung und pharmazeutische zusammensetzungen
IL112588A0 (en) Imidazo [1,2-a] quinoxalinone derivatives, their preparation and pharmaceutical compositions containing them
ES8604104A1 (es) Un procedimiento para la preparacion de nuevos derivados de feniletanamina
ES8101045A1 (es) Procedimiento para la preparacion de derivados de acidos pi-rrolidinilsulfamoilbenzoicos sustituidos
HUP9902606A2 (hu) Mátrix metalloproteináz inhibitorok
GB1505848A (en) 3,4-dicarboxycephalosporins and derivatives
IL99819A0 (en) Imidazole-2-yl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
MX9804365A (es) Derivados novedosos de indolo-2,3-diono-3-oxima.